Drugs / PENTABORATE
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02241811 | Sep 2014 → Dec 2021 | — | SB Istanbul Education and Research Hospital | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06840054 | May 2025 → Jan 2026 overdue | Alzheimer disease | Tabriz University of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06809816 | Mar → Aug 2025 overdue | postmenopausal osteoporosis | Tabriz University of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04239560 | Feb → Sep 2019 | radiodermatitis | Tabriz University of Medical Sciences | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05741606 Comparator | Jul 2023 → Mar 2024 | morbid obesity | Tabriz University of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PENTABORATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316166 ↗ |
| Known as | Sodium Pentaborate Pentahydrate | “Patients in intervention and placebo groups received daily a gel containing 3% sodium pentaborate pentahydrate and gel free of any chemical treatment respectively 15 minutes...” NCT04239560 ↗ |
| Modality | Small molecule | — CHEMBL5316166 ↗ |
| Route | Oral | “Participants will be randomly assigned (6:1) to oral administration of once-daily sodium pentaborate pentahydrate (200, 400, 600, 800, 1000 mg), or placebo, using balanced...” NCT05741606 ↗ |